zinc finger and BTB domain containing 25Genealiases: C14orf51 · KUP · ZNF46
Q-omics provides the consensus-scored ZBTB25 profile across patient tissues and cancer cell-line models. ZBTB25 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZBTB25 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ZBTB25 RNA expression shows 21,166 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, HNSC, and ACC as cancer lineages where ZBTB25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB25 survival associations across molecular data types. ZBTB25 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB25 RNA expression–survival associations across cancer types. High ZBTB25 expression shows unfavorable associations in UVM, KIRP and ACC, but favorable associations in BRCA, SKCM and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZBTB25 RNA expression.
This table summarizes ZBTB25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB25 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, KIRP and CHOL. The HNSC box plot shows higher ZBTB25 RNA expression in tumor versus normal tissue (log2 FC = +0.499, t-test p < 0.001).
This table shows molecular features associated with ZBTB25 in patient tissues and cancer cell lines. In patient samples, ZBTB25 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
